{
  "parsed": [
    {
      "model": "claude",
      "raw": "\u2500\u2500\u2500 SECTION 1: DECOMPOSITION \u2500\u2500\u2500\n\n**Sub-questions:**\n1. **What is the mechanistic hierarchy?** Is HK-II displacement a permissive event (necessary but insufficient) or the primary death signal itself? The distinction matters: if permissive, then downstream lipid-dependent oligomerization is the actual commitment step.\n2. **How does the HK-II \"buffer capacity\" quantitatively interact with CBD's Kd (11 \u00b5M)?** Given HK-II binds VDAC1 at sub-nM affinity, what mass-action concentration of CBD is required for meaningful displacement, and does this match observed cytotoxicity thresholds?\n3. **Is cofactor removal additive or cooperative?** Do HK-II and Bcl-xL constitute independent or coupled brakes on VDAC1 oligomerization?\n4. **How do membrane lipids (cardiolipin, cholesterol) modulate the oligomerization threshold independently of cofactor occupancy?**\n\n**Key variables:** [CBD], HK-II occupancy fraction, Bcl-xL occupancy, cardiolipin/cholesterol ratio, VDAC1 oligomer density, Bax insertion competence.\n\n\u2500\u2500\u2500 SECTION 2: CLAIMS \u2500\u2500\u2500\n\n**CLAIM 1:** HK-II displacement is necessary but insufficient for cytochrome c release; the commitment point is VDAC1 oligomerization into a cytochrome c\u2013permeable supercomplex, which requires concurrent loss of Bcl-xL restraint AND permissive lipid environment (cardiolipin exposure).\nTYPE: 2\nCONFIDENCE: 0.72\nMECHANISM: HK-II removal unmasks VDAC1's N-terminal oligomerization interface, but stable oligomers only form when Bcl-xL is absent and cardiolipin provides the membrane curvature/electrostatic environment for Bax co-recruitment.\nFALSIFIABLE BY: Demonstrating that HK-II displacement alone (e.g., via methyl jasmonate) in Bcl-xL\u2013overexpressing or cardiolipin-depleted cells still triggers equivalent cytochrome c release.\n\n**CLAIM 2:** The Warburg phenotype creates a biphasic dose-response with a sharp inflection, not a gradual curve. At [CBD] < Kd (< 11 \u00b5M), VDAC1 occupancy by HK-II remains >90% due to affinity mismatch (HK-II Kd ~nM vs CBD Kd = 11 \u00b5M), and cytoprotective targets (TRPV1 Kd=2 \u00b5M, PPAR\u03b3 EC50=5 \u00b5M) dominate. Above ~15\u201320 \u00b5M, cooperative displacement occurs because HK-II binding is stabilized by G6P product; once metabolic flux is disrupted, HK-II affinity drops, creating a positive-feedback collapse.\nTYPE: 2\nCONFIDENCE: 0.68\nMECHANISM: CBD at sub-Kd concentrations cannot compete with nM-affinity HK-II, but at supra-Kd concentrations, metabolic disruption (reduced ATP, altered G6P) destabilizes HK-II binding cooperatively, producing switch-like displacement.\nFALSIFIABLE BY: Measuring HK-II-VDAC1 co-IP across a CBD dose range showing gradual rather than switch-like displacement; or showing G6P levels don't change HK-II's VDAC1 affinity.\n\n**CLAIM 3:** 2-DG + ABT-737 synergy is supra-additive because they collapse two independent stabilizing clamps simultaneously, lowering the effective CBD concentration needed for apoptosis from ~20 \u00b5M to within the therapeutic window (1\u201310 \u00b5M).\nTYPE: 2\nCONFIDENCE: 0.65\nMECHANISM: 2-DG depletes G6P, reducing HK-II's VDAC1 residence time; ABT-737 removes Bcl-xL; together they lower the oligomerization threshold so that even partial VDAC1 occupancy by CBD triggers commitment.\nFALSIFIABLE BY: Bliss independence analysis showing additivity rather than synergy in a 2-DG/ABT-737/CBD triple combination matrix.\n\n**CLAIM 4:** Cardiolipin enrichment at the OMM lowers the apoptotic threshold by ~2-fold by stabilizing VDAC1 oligomers and facilitating Bax insertion, while cholesterol opposes this by rigidifying the membrane and stabilizing monomeric VDAC1.\nTYPE: 3\nCONFIDENCE: 0.45\nMECHANISM: Cardiolipin's cone-shaped geometry promotes negative curvature at oligomer interfaces; cholesterol increases bilayer order, raising the energy barrier for conformational transitions required for oligomerization.\nFALSIFIABLE BY: Reconstituting VDAC1 in liposomes of defined CL/cholesterol ratios and measuring oligomerization kinetics \u00b1 CBD; no lipid dependence would refute this.\n\n\u2500\u2500\u2500",
      "claims": [
        {
          "statement": "1:** HK-II displacement is necessary but insufficient for cytochrome c release; the commitment point is VDAC1 oligomerization into a cytochrome c\u2013permeable supercomplex, which requires concurrent loss of Bcl-xL restraint AND permissive lipid environment (cardiolipin exposure).",
          "type": 2,
          "confidence": 0.72,
          "mechanism": "HK-II removal unmasks VDAC1's N-terminal oligomerization interface, but stable oligomers only form when Bcl-xL is absent and cardiolipin provides the membrane curvature/electrostatic environment for Bax co-recruitment.",
          "falsifiable_by": "Demonstrating that HK-II displacement alone (e.g., via methyl jasmonate) in Bcl-xL\u2013overexpressing or cardiolipin-depleted cells still triggers equivalent cytochrome c release."
        },
        {
          "statement": "2:** The Warburg phenotype creates a biphasic dose-response with a sharp inflection, not a gradual curve. At [CBD] < Kd (< 11 \u00b5M), VDAC1 occupancy by HK-II remains >90% due to affinity mismatch (HK-II Kd ~nM vs CBD Kd = 11 \u00b5M), and cytoprotective targets (TRPV1 Kd=2 \u00b5M, PPAR\u03b3 EC50=5 \u00b5M) dominate. Above ~15\u201320 \u00b5M, cooperative displacement occurs because HK-II binding is stabilized by G6P product; once metabolic flux is disrupted, HK-II affinity drops, creating a positive-feedback collapse.",
          "type": 2,
          "confidence": 0.68,
          "mechanism": "CBD at sub-Kd concentrations cannot compete with nM-affinity HK-II, but at supra-Kd concentrations, metabolic disruption (reduced ATP, altered G6P) destabilizes HK-II binding cooperatively, producing switch-like displacement.",
          "falsifiable_by": "Measuring HK-II-VDAC1 co-IP across a CBD dose range showing gradual rather than switch-like displacement; or showing G6P levels don't change HK-II's VDAC1 affinity."
        },
        {
          "statement": "3:** 2-DG + ABT-737 synergy is supra-additive because they collapse two independent stabilizing clamps simultaneously, lowering the effective CBD concentration needed for apoptosis from ~20 \u00b5M to within the therapeutic window (1\u201310 \u00b5M).",
          "type": 2,
          "confidence": 0.65,
          "mechanism": "2-DG depletes G6P, reducing HK-II's VDAC1 residence time; ABT-737 removes Bcl-xL; together they lower the oligomerization threshold so that even partial VDAC1 occupancy by CBD triggers commitment.",
          "falsifiable_by": "Bliss independence analysis showing additivity rather than synergy in a 2-DG/ABT-737/CBD triple combination matrix."
        },
        {
          "statement": "4:** Cardiolipin enrichment at the OMM lowers the apoptotic threshold by ~2-fold by stabilizing VDAC1 oligomers and facilitating Bax insertion, while cholesterol opposes this by rigidifying the membrane and stabilizing monomeric VDAC1.",
          "type": 3,
          "confidence": 0.45,
          "mechanism": "Cardiolipin's cone-shaped geometry promotes negative curvature at oligomer interfaces; cholesterol increases bilayer order, raising the energy barrier for conformational transitions required for oligomerization.",
          "falsifiable_by": "Reconstituting VDAC1 in liposomes of defined CL/cholesterol ratios and measuring oligomerization kinetics \u00b1 CBD; no lipid dependence would refute this. \u2500\u2500\u2500"
        }
      ]
    },
    {
      "model": "mistral",
      "raw": "---\n### **SECTION 1: DECOMPOSITION**\n**Sub-questions:**\n1. **Does HK-II displacement trigger cytochrome c release via lipid exposure (CL peroxidation) rather than direct VDAC1 conductance changes?**\n   *Key variables:* HK-II occupancy, CL oxidation state, Bax recruitment, VDAC1 conductance, cyt c release kinetics.\n   *Relationship:* HK-II displacement \u2192 CL exposure \u2192 Bax/peroxidation \u2192 cyt c release (vs. VDAC1 conductance as primary driver).\n\n2. **How does the Warburg phenotype create a biphasic CBD response?**\n   *Key variables:* CBD dose, HK-II-VDAC1 affinity (sub-nM), TRPV1/PPAR\u03b3 engagement (Kd/EC50 2\u20135 \u00b5M), metabolic ATP flux.\n   *Relationship:* Low [CBD] (<5 \u00b5M) \u2192 HK-II-bound VDAC1 + TRPV1/PPAR\u03b3 survival \u2192 cytoprotection; high [CBD] (>15 \u00b5M) \u2192 HK-II displacement \u2192 apoptosis.\n\n3. **Can cofactor manipulation (2-DG, ABT-737) predictably shift the VDAC1 \"decision gate\"?**\n   *Key variables:* HK-II/Bcl-xL occupancy, VDAC1 oligomerization threshold, lipid composition (CL/cholesterol).\n   *Relationship:* 2-DG (HK-II displacement) + ABT-737 (Bcl-xL displacement) \u2192 supra-additive removal of anti-apoptotic clamps \u2192 apoptosis.\n\n4. **Do membrane lipids (CL/cholesterol) allosterically gate VDAC1 oligomerization?**\n   *Key variables:* CL/cholesterol ratio, VDAC1 oligomerization kinetics, Bax insertion efficiency.\n   *Relationship:* CL \u2192 promotes oligomerization/Bax insertion \u2192 lowers apoptotic threshold; cholesterol \u2192 inhibits \u2192 raises threshold.\n\n---\n\n### **SECTION 2: CLAIMS**\n\n**CLAIM 1:** HK-II displacement by CBD/erastin is the *primary* death signal, with cytochrome c release driven by CL peroxidation (via Bax recruitment) rather than direct VDAC1 conductance changes.\n**TYPE:** 1 (mechanistic, supported by prior convergence)\n**CONFIDENCE:** 0.85\n**MECHANISM:** Displaced HK-II unmasks CL, enabling Bax-mediated CL peroxidation and cyt c release, while VDAC1 conductance changes are secondary to lipid-dependent oligomerization.\n**FALSIFIABLE BY:**\n- HK-II mutants that bind VDAC1 but do not shield CL (e.g., HK-II \u0394N-terminal) fail to prevent cyt c release upon CBD/erastin treatment.\n- CL-deficient mitochondria (e.g., *Taz* knockdown) show no cyt c release despite HK-II displacement.\n- Direct VDAC1 conductance modulation (e.g., ruthenium red) without HK-II displacement fails to trigger apoptosis.\n\n---\n\n**CLAIM 2:** The Warburg phenotype (high HK-II-VDAC1 coupling) creates a biphasic CBD response: cytoprotection at low doses (<5 \u00b5M) via TRPV1/PPAR\u03b3 survival signaling, and apoptosis at high doses (>15 \u00b5M) via HK-II displacement and anti-apoptotic reserve saturation.\n**TYPE:** 1 (quantitative, supported by priors)\n**CONFIDENCE:** 0.80\n**MECHANISM:** At low [CBD], fractional VDAC1 occupancy is minimal (Kd=11 \u00b5M vs. HK-II sub-nM affinity), preserving glycolytic ATP and TRPV1/PPAR\u03b3-mediated survival; at high [CBD], mass-action displacement of HK-II removes metabolic shielding and triggers oligomerization.\n**FALSIFIABLE BY:**\n- HK-II overexpression in non-Warburg cells (e.g., fibroblasts) recapitulates the biphasic response.\n- TRPV1/PPAR\u03b3 antagonists (e.g., capsazepine, GW9662) abolish cytoprotection at low [CBD] without affecting high-dose apoptosis.\n- CBD analogs with higher VDAC1 affinity (Kd < 1 \u00b5M) eliminate the protective phase.\n\n---\n\n**CLAIM 3:** 2-DG + ABT-737 synergistically shift the VDAC1 decision gate toward apoptosis by simultaneously removing HK-II (metabolic clamp) and Bcl-xL (signaling clamp), lowering the apoptotic threshold [CBD] by \u22653-fold.\n**TYPE:** 1 (therapeutic prediction)\n**CONFIDENCE:** 0.75\n**MECHANISM:** 2-DG reduces HK-II\u2019s VDAC1 affinity (product-dependent binding), while ABT-737 liberates Bcl-xL, removing two independent brakes on VDAC1 oligomerization and Bax insertion.\n**FALSIFIABLE BY:**\n- Single-agent 2-DG or ABT-737 fails to lower the apoptotic [CBD] threshold to the same extent as the combination.\n- Bcl-xL mutants with reduced VDAC1 affinity (e.g., Bcl-xL \u0394TM) abrogate synergy with 2-DG.\n- VDAC1 oligomerization assays (e.g., FRET) show no supra-additive increase with 2-DG + ABT-737.\n\n---\n\n**CLAIM 4:** Cardiolipin (CL) enrichment in the OMM lowers the apoptotic threshold for CBD by ~2\u20133-fold (EC50 shift from ~20 \u00b5M to ~8 \u00b5M) by promoting VDAC1 oligomerization and Bax insertion, while cholesterol elevation raises it equivalently.\n**TYPE:**",
      "claims": [
        {
          "statement": "1:** HK-II displacement by CBD/erastin is the *primary* death signal, with cytochrome c release driven by CL peroxidation (via Bax recruitment) rather than direct VDAC1 conductance changes.",
          "type": 1,
          "confidence": 0.85,
          "mechanism": "Displaced HK-II unmasks CL, enabling Bax-mediated CL peroxidation and cyt c release, while VDAC1 conductance changes are secondary to lipid-dependent oligomerization.",
          "falsifiable_by": "- HK-II mutants that bind VDAC1 but do not shield CL (e.g., HK-II \u0394N-terminal) fail to prevent cyt c release upon CBD/erastin treatment. - CL-deficient mitochondria (e.g., *Taz* knockdown) show no cyt c release despite HK-II displacement. - Direct VDAC1 conductance modulation (e.g., ruthenium red) without HK-II displacement fails to trigger apoptosis. ---"
        },
        {
          "statement": "2:** The Warburg phenotype (high HK-II-VDAC1 coupling) creates a biphasic CBD response: cytoprotection at low doses (<5 \u00b5M) via TRPV1/PPAR\u03b3 survival signaling, and apoptosis at high doses (>15 \u00b5M) via HK-II displacement and anti-apoptotic reserve saturation.",
          "type": 1,
          "confidence": 0.8,
          "mechanism": "At low [CBD], fractional VDAC1 occupancy is minimal (Kd=11 \u00b5M vs. HK-II sub-nM affinity), preserving glycolytic ATP and TRPV1/PPAR\u03b3-mediated survival; at high [CBD], mass-action displacement of HK-II removes metabolic shielding and triggers oligomerization.",
          "falsifiable_by": "- HK-II overexpression in non-Warburg cells (e.g., fibroblasts) recapitulates the biphasic response. - TRPV1/PPAR\u03b3 antagonists (e.g., capsazepine, GW9662) abolish cytoprotection at low [CBD] without affecting high-dose apoptosis. - CBD analogs with higher VDAC1 affinity (Kd < 1 \u00b5M) eliminate the protective phase. ---"
        },
        {
          "statement": "3:** 2-DG + ABT-737 synergistically shift the VDAC1 decision gate toward apoptosis by simultaneously removing HK-II (metabolic clamp) and Bcl-xL (signaling clamp), lowering the apoptotic threshold [CBD] by \u22653-fold.",
          "type": 1,
          "confidence": 0.75,
          "mechanism": "2-DG reduces HK-II\u2019s VDAC1 affinity (product-dependent binding), while ABT-737 liberates Bcl-xL, removing two independent brakes on VDAC1 oligomerization and Bax insertion.",
          "falsifiable_by": "- Single-agent 2-DG or ABT-737 fails to lower the apoptotic [CBD] threshold to the same extent as the combination. - Bcl-xL mutants with reduced VDAC1 affinity (e.g., Bcl-xL \u0394TM) abrogate synergy with 2-DG. - VDAC1 oligomerization assays (e.g., FRET) show no supra-additive increase with 2-DG + ABT-737. ---"
        },
        {
          "statement": "4:** Cardiolipin (CL) enrichment in the OMM lowers the apoptotic threshold for CBD by ~2\u20133-fold (EC50 shift from ~20 \u00b5M to ~8 \u00b5M) by promoting VDAC1 oligomerization and Bax insertion, while cholesterol elevation raises it equivalently.",
          "type": 2,
          "confidence": 0.5,
          "mechanism": "",
          "falsifiable_by": ""
        }
      ]
    },
    {
      "model": "grok",
      "raw": "\u2500\u2500\u2500 \n\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\nSECTION 1: DECOMPOSITION\n\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\nSub-questions: \n1. Does cofactor displacement (HK-II > Bcl-xL > tubulin) by CBD/erastin dictate cyt c release primacy over VDAC conductance? \n2. How does Warburg (high HK-II-VDAC occupancy) create biphasic CBD response within therapeutic window (1-10 \u00b5M)?\n3. Do lipids (high CL pro-apo, high chol anti-apo) allosterically tune the cofactor-free VDAC oligomerization threshold?\n4. Can combo Rx (2-DG displ HK-II, ABT-737 displ Bcl-xL) quantitatively predict gate-shift (survival\u2192death)?\n\nKey variables/relations: [CBD] vs Kd=11 \u00b5M competes HK-II (sub-nM aff.) occupancy \u2192 free VDAC density; Bcl-xL/tubulin clamps modulate oligomerization; CL exposes/peroxidizes cyt c, chol stabilizes closed state; Warburg buffers low-[CBD] via glycolysis shield + TRPV1/PPAR\u03b3 (Kd/EC50 2-5 \u00b5M).\n\n\u2500\u2500\u2500 SECTION 2: CLAIMS \u2500\u2500\u2500\nCLAIM: HK-II displacement by CBD/erastin is the primary cyt c release trigger via CL unmasking/peroxidation, secondary to VDAC conductance change; tubulin blockade acts redundantly but weaker.\nTYPE: 1\nCONFIDENCE: 0.82\nMECHANISM: HK-II shields OMM CL from peroxidation/Bax; displacement exposes CL, recruiting Bax/oligomerizing VDAC for cyt c egress independent of channel pore dilation.\nFALSIFIABLE BY: HK-II KD cells show no cyt c release or attenuated response to CBD/erastin despite conductance increase (patch-clamp + cyt c assay).\n\nCLAIM: Warburg high HK-II-VDAC occupancy (>80%) protects vs low CBD (1-5 \u00b5M, <50% displacement) via glycolytic ATP + TRPV1/PPAR\u03b3 cytoprotection (EC50 2-5 \u00b5M), but sensitizes at high (15+ \u00b5M) by saturating HK-II buffer (mass-action >Kd=11 \u00b5M).\nTYPE: 1\nCONFIDENCE: 0.79\nMECHANISM: Low [CBD] fractional occupancy f=[CBD]/( [CBD]+Kd ) ~0.3-0.5 leaves HK-II dominant; high [CBD] f>0.8 displaces HK-II, collapsing metabolic shield while Bcl-xL reserves deplete.\nFALSIFIABLE BY: Non-Warburg cells (low HK-II) show inverted dose-response (death at low CBD) in viability curves vs Warburg lines.\n\nCLAIM: CL enrichment lowers apoptotic [CBD] EC50 ~2-3x (11\u21924-6 \u00b5M) by promoting VDAC oligomerization/Bax insertion; cholesterol raises it equivalently by rigidifying OMM/anti-oligomer.\nTYPE: 2\nCONFIDENCE: 0.68\nMECHANISM: CL peroxidation post-HK-II displacement facilitates VDAC hexamer cyt c channel; chol stabilizes monomeric low-conductance VDAC, blocking allosteric apo-gate.\nFALSIFIABLE BY: OMM liposome swaps (high/low CL/chol) +/- CBD show no EC50 shift in cyt c flux or Bax binding (lipidomics + proteomics).\n\nCLAIM: 2-DG + ABT-737 shifts gate supra-additively (CI<0.8): apoptotic [CBD] threshold \u221d 1 / [(1-HK-II occ.) \u00d7 (1-Bcl-xL occ.)]; predicts 5-10x sensitization in high-cofactor cancers.\nTYPE: 2\nCONFIDENCE: 0.71\nMECHANISM: 2-DG reduces HK-II-VDAC affinity (G6P competition); ABT-737 frees Bcl-xL; dual removal exceeds linear free-VDAC for oligomer threshold (~30% free monomers).\nFALSIFIABLE BY: Isobologram in HK-II/Bcl-xL OE vs KD cells shows additivity (CI=1) not synergy.\n\nCLAIM: Tubulin blockade reinforces Bcl-xL but not HK-II; its displacement by CBD requires >20 \u00b5M, contributing <20% to gate-shift.\nTYPE: 3\nCONFIDENCE: 0.55\nMECHANISM: Microtubule-detached tubulin plugs VDAC semi-independently of HK-II, but low-affinity binding yields minor cytoprotection vs dominant metabolic HK-II.\nFALSIFIABLE BY: Vinblastine (tubulin stabilizer) + low CBD blocks death in HK-II-low cells only.\n\n\u2500\u2500\u2500 SECTION 3: UNKNOWNS \u2500\u2500\u2500\nMissing: HK-II-VDAC Kd/Koff (est. sub-nM/static?); Bcl-xL-VDAC Kd; fractional occupancies in Warburg OMM (cryo-EM); CBD-induced peroxidation kinetics (lipid-MS); tubulin-VDAC Kd; in vivo [CBD]OMM (1-10 \u00b5M plasma \u2192 ? local).\n\n\u2500\u2500\u2500 SECTION 4: NEXT STEP \u2500\u2500\u2500\nCRISPR HK-II/Bcl-xL KD in Warburg lines: CBD dose-response cyt c/ viability +/- 2-DG/ABT-737; quantify occupancies (co-IP + MS).\n\n\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550",
      "claims": [
        {
          "statement": "HK-II displacement by CBD/erastin is the primary cyt c release trigger via CL unmasking/peroxidation, secondary to VDAC conductance change; tubulin blockade acts redundantly but weaker.",
          "type": 1,
          "confidence": 0.82,
          "mechanism": "HK-II shields OMM CL from peroxidation/Bax; displacement exposes CL, recruiting Bax/oligomerizing VDAC for cyt c egress independent of channel pore dilation.",
          "falsifiable_by": "HK-II KD cells show no cyt c release or attenuated response to CBD/erastin despite conductance increase (patch-clamp + cyt c assay)."
        },
        {
          "statement": "Warburg high HK-II-VDAC occupancy (>80%) protects vs low CBD (1-5 \u00b5M, <50% displacement) via glycolytic ATP + TRPV1/PPAR\u03b3 cytoprotection (EC50 2-5 \u00b5M), but sensitizes at high (15+ \u00b5M) by saturating HK-II buffer (mass-action >Kd=11 \u00b5M).",
          "type": 1,
          "confidence": 0.79,
          "mechanism": "Low [CBD] fractional occupancy f=[CBD]/( [CBD]+Kd ) ~0.3-0.5 leaves HK-II dominant; high [CBD] f>0.8 displaces HK-II, collapsing metabolic shield while Bcl-xL reserves deplete.",
          "falsifiable_by": "Non-Warburg cells (low HK-II) show inverted dose-response (death at low CBD) in viability curves vs Warburg lines."
        },
        {
          "statement": "CL enrichment lowers apoptotic [CBD] EC50 ~2-3x (11\u21924-6 \u00b5M) by promoting VDAC oligomerization/Bax insertion; cholesterol raises it equivalently by rigidifying OMM/anti-oligomer.",
          "type": 2,
          "confidence": 0.68,
          "mechanism": "CL peroxidation post-HK-II displacement facilitates VDAC hexamer cyt c channel; chol stabilizes monomeric low-conductance VDAC, blocking allosteric apo-gate.",
          "falsifiable_by": "OMM liposome swaps (high/low CL/chol) +/- CBD show no EC50 shift in cyt c flux or Bax binding (lipidomics + proteomics)."
        },
        {
          "statement": "2-DG + ABT-737 shifts gate supra-additively (CI<0.8): apoptotic [CBD] threshold \u221d 1 / [(1-HK-II occ.) \u00d7 (1-Bcl-xL occ.)]; predicts 5-10x sensitization in high-cofactor cancers.",
          "type": 2,
          "confidence": 0.71,
          "mechanism": "2-DG reduces HK-II-VDAC affinity (G6P competition); ABT-737 frees Bcl-xL; dual removal exceeds linear free-VDAC for oligomer threshold (~30% free monomers).",
          "falsifiable_by": "Isobologram in HK-II/Bcl-xL OE vs KD cells shows additivity (CI=1) not synergy."
        },
        {
          "statement": "Tubulin blockade reinforces Bcl-xL but not HK-II; its displacement by CBD requires >20 \u00b5M, contributing <20% to gate-shift.",
          "type": 3,
          "confidence": 0.55,
          "mechanism": "Microtubule-detached tubulin plugs VDAC semi-independently of HK-II, but low-affinity binding yields minor cytoprotection vs dominant metabolic HK-II.",
          "falsifiable_by": "Vinblastine (tubulin stabilizer) + low CBD blocks death in HK-II-low cells only. \u2500\u2500\u2500"
        }
      ]
    },
    {
      "model": "gemini",
      "raw": "\u2500\u2500\u2500\n\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\nINDEPENDENT CONSENSUS \u2014 FROM PREVIOUS CYCLE\n\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\n\nThe following claims showed independent convergence across multiple\nmirrors in the previous cycle. No mirror saw another's output \u2014\nthis convergence emerged independently. Go deeper on these threads:\nexplore mechanisms, quantitative predictions, and falsification conditions.\n\n  [ESTABLISHED] 1:** HK-II displacement by CBD/erastin is the *primary* death signal, with cytochrome c release driven by CL exposure (via lipid peroxidation) rather than direct VDAC1 conductance changes.\n    MECHANISM: Displaced HK-II unmasks CL, enabling Bax recruitment and peroxidation-sensitive cyt c release, while VDAC1 conductance changes are secondary.\n    OVERLAP: 4/5 mirrors | CONFIDENCE: 0.742\n\n  [ESTABLISHED] 2:** The Warburg phenotype dictates a biphasic CBD response due to competitive binding kinetics between CBD (Kd=11 \u00b5M) and HK-II (estimated sub-nM affinity for VDAC1) across a concentration gradient, creating a \"HK-II buffer\" that must be saturated before apoptosis is triggered.\n    MECHANISM: At low [CBD] (<5 \u00b5M), fractional occupancy of VDAC1 is minimal; HK-II remains bound, maintaining glycolytic ATP and metabolic survival signaling, while concurrent engagement of TRPV1/PPAR\u03b3 (lower Kd/EC50) promotes cytoprotection. At high [CBD] (>15 \u00b5M), mass-action displacement of HK-II occurs, removing the metabolic shield and initiating the oligomerization cascade.\n    OVERLAP: 4/5 mirrors | CONFIDENCE: 0.737\n\n  [REPLICATED] 3:** 2-DG + ABT-737 synergistically shifts the VDAC1 decision gate toward apoptosis, and this synergy is supra-additive because they target two independent anti-apoptotic clamps on the same oligomerization pathway.\n    MECHANISM: 2-DG competes with glucose-6-phosphate for HK-II, reducing HK-II's VDAC1 affinity (product-dependent binding), while ABT-737 directly liberates Bcl-xL from VDAC1; together they simultaneously remove the structural (HK-II) and signaling (Bcl-xL) brakes on VDAC1 oligomerization.\n    OVERLAP: 3/5 mirrors | CONFIDENCE: 0.673\n\n\nSINGULAR THREADS (1 mirror only \u2014 potential novel insights):\n  [SINGULAR] Warburg phenotype (high HK-II-VDAC occupancy) protects cancer cells from low-dose CBD (<5 \u00b5M, sub-Kd) via stabilized glycolysis + TRPV1/PPAR\u03b3 survival (Kds 2-5 \u00b5M), but sensitizes at high doses (>11 \u00b5M) by saturating anti-apo reserves (Bcl-xL).\n    SOURCE: grok | CONFIDENCE: 0.78\n  [SINGULAR] The final commitment to apoptosis requires a threshold density of cofactor-free VDAC1 to oligomerize into a Bax/Bak-receptive supercomplex, a process allosterically gated by membrane lipids.\n    SOURCE: gemini | CONFIDENCE: 0.7\n  [SINGULAR] 1:** HK-II displacement from VDAC1 is a necessary but insufficient permissive step for cytochrome c release; the primary death signal is the subsequent, lipid-facilitated VDAC1 oligomerization or conformational shift to a sustained high-conductance state.\n    SOURCE: deepseek | CONFIDENCE: 0.7\n  [SINGULAR] 3:** The \"decision gate\" can be quantitatively tuned by cofactor manipulation: the apoptotic threshold [CBD] is inversely proportional to the product of (1 - HK-II occupancy) and (1 - Bcl-xL occupancy).\n    SOURCE: deepseek | CONFIDENCE: 0.6\n  [SINGULAR] 4:** Cardiolipin enrichment in the OMM lowers the apoptotic threshold by ~2-3 fold (reducing effective CBD EC50 for death from ~20 \u00b5M to ~8 \u00b5M) by promoting VDAC1 oligomerization and Bax insertion, while cholesterol elevation raises it equivalently.\n    SOURCE: claude | CONFIDENCE: 0.45\n\nOne mirror saw these \u2014 investigate whether they're real. If you find supporting evidence, include them.\n\nNOTE: Previous cycle achieved 61% TYPE 0/1 overlap. Explore mechanisms and quantitative predictions for converged claims. Investigate singular threads for potential novel discoveries.\n\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\n\nSECTION 1: DECOMPOSITION (max 200 tokens) \u2500\u2500\u2500\n1.  **Mechanism of Action:** Is the primary cytotoxic signal from VDAC1-targeting molecules the displacement of cofactors (HK-II, Bcl-xL), a direct alteration of VDAC1 conductance, or the subsequent oligomerization of cofactor-free VDAC1 into a pro-apoptotic supercomplex?\n2.  **Dose-Response Bifurcation:** How does the interplay between CBD's affinity for multiple targets (VDAC1, TRPV1/2, PPAR\u03b3) and the high expression of HK-II in Warburg cells create a biphasic (cytoprotective vs. cytotoxic) dose-response curve?\n3.  **Landscape Modulation:** Can the VDAC1 apoptotic threshold be predictably tuned by manipulating the cofactor landscape (HK-II, Bcl-xL occupancy) and the allosteric lipid environment (cardiolipin, cholesterol)? Key variables are protein occupancy fractions and membrane lipid ratios.\n\n\u2500\u2500\u2500 SECTION 2: CLAIMS (max 400 tokens) \u2500\u2500\u2500\n\nCLAIM: HK-II displacement is a necessary permissive event, but the irreversible death commitment is the subsequent VDAC1 oligomerization into a Bax/Bak-receptive macropore, a process allosterically promoted by exposed cardiolipin.\nTYPE: 1\nCONFIDENCE: 0.85\nMECHANISM: Displacing HK-II unmasks VDAC1 and its proximal cardiolipin, creating a nucleation site for both VDAC1 self-assembly and Bax insertion, which are the true points of no return.\nFALSIFIABLE BY: Evidence showing that a non-oligomerizing VDAC1 mutant, when HK-II is displaced, still permits Bax/Bak-mediated cytochrome c release at the same rate as wild-type.\n\nCLAIM: The Warburg phenotype's biphasic response to CBD is a direct consequence of its target affinity profile: low doses (<5 \u00b5M) favor cytoprotective TRPV1/PPAR\u03b3 signaling (EC50 2-5 \u00b5M), while cytotoxic effects only manifest when CBD concentrations approach VDAC1's Kd (11 \u00b5M) and can overcome the high-affinity HK-II \"buffer.\"\nTYPE: 1\nCONFIDENCE: 0.90\nMECHANISM: CBD follows mass-action kinetics, engaging its highest-affinity targets first; protective signaling is initiated before the concentration is sufficient to achieve the high VDAC1 occupancy required for HK-II displacement and apoptosis.\nFALSIFIABLE BY: A highly specific VDAC1-binding CBD analog (Kd < 1 \u00b5M) failing to induce apoptosis at low doses in Warburg cells.\n\nCLAIM: The apoptotic threshold [Drug] for a VDAC1-targeting agent is inversely proportional to the fraction of \"free\" VDAC1, defined as VDAC1 not bound by either HK-II or Bcl-xL, and directly proportional to the membrane cholesterol:cardiolipin ratio.\nTYPE: 2\nCONFIDENCE: 0.75\nMECHANISM: Both HK-II/Bcl-xL and cholesterol act as independent negative regulators of VDAC1 oligomerization, increasing the activation energy that must be overcome by the drug binding event.\nFALSIFIABLE BY: A cell line with engineered high cholesterol and low HK-II expression showing the same apoptotic sensitivity to CBD as a low cholesterol, low HK-II line.\n\n\u2500\u2500\u2500 SECTION 3: UNKNOWNS (max 150 tokens) \u2500\u2500\u2500\n1.  The *in situ* binding affinity (Kd) of HK-II for VDAC1 in a metabolically active, high-glycolysis cancer cell. The sub-nanomolar estimate is a critical but unverified assumption.\n2.  The stoichiometry and structure of the final apoptotic VDAC1-Bax/Bak pore. Is it a defined oligomer, or a less-ordered protein-lipid pore?\n3.  The quantitative relationship between membrane cholesterol content and the VDAC1 oligomerization rate constant.\n4.  The direct binding affinity of tubulin for VDAC1 and whether this interaction is competitive with HK-II or Bcl-xL.\n\n\u2500\u2500\u2500 SECTION 4: NEXT STEP (max 50 tokens) \u2500\u2500\u2500\nUse cryo-electron tomography on mitochondria from Warburg cells treated with low vs. high dose CBD to directly visualize VDAC1 oligomerization state and its spatial relationship with Bax/Bak and HK-II.",
      "claims": [
        {
          "statement": "HK-II displacement is a necessary permissive event, but the irreversible death commitment is the subsequent VDAC1 oligomerization into a Bax/Bak-receptive macropore, a process allosterically promoted by exposed cardiolipin.",
          "type": 1,
          "confidence": 0.85,
          "mechanism": "Displacing HK-II unmasks VDAC1 and its proximal cardiolipin, creating a nucleation site for both VDAC1 self-assembly and Bax insertion, which are the true points of no return.",
          "falsifiable_by": "Evidence showing that a non-oligomerizing VDAC1 mutant, when HK-II is displaced, still permits Bax/Bak-mediated cytochrome c release at the same rate as wild-type."
        },
        {
          "statement": "The Warburg phenotype's biphasic response to CBD is a direct consequence of its target affinity profile: low doses (<5 \u00b5M) favor cytoprotective TRPV1/PPAR\u03b3 signaling (EC50 2-5 \u00b5M), while cytotoxic effects only manifest when CBD concentrations approach VDAC1's Kd (11 \u00b5M) and can overcome the high-affinity HK-II \"buffer.\"",
          "type": 1,
          "confidence": 0.9,
          "mechanism": "CBD follows mass-action kinetics, engaging its highest-affinity targets first; protective signaling is initiated before the concentration is sufficient to achieve the high VDAC1 occupancy required for HK-II displacement and apoptosis.",
          "falsifiable_by": "A highly specific VDAC1-binding CBD analog (Kd < 1 \u00b5M) failing to induce apoptosis at low doses in Warburg cells."
        },
        {
          "statement": "The apoptotic threshold [Drug] for a VDAC1-targeting agent is inversely proportional to the fraction of \"free\" VDAC1, defined as VDAC1 not bound by either HK-II or Bcl-xL, and directly proportional to the membrane cholesterol:cardiolipin ratio.",
          "type": 2,
          "confidence": 0.75,
          "mechanism": "Both HK-II/Bcl-xL and cholesterol act as independent negative regulators of VDAC1 oligomerization, increasing the activation energy that must be overcome by the drug binding event.",
          "falsifiable_by": "A cell line with engineered high cholesterol and low HK-II expression showing the same apoptotic sensitivity to CBD as a low cholesterol, low HK-II line. \u2500\u2500\u2500"
        }
      ]
    },
    {
      "model": "deepseek",
      "raw": "\u2500\u2500\u2500 \n\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\nINDEPENDENT CONSENSUS \u2014 FROM PREVIOUS CYCLE\n\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\n\n[I have reviewed the established and singular threads. My reasoning will build upon and test these convergences, particularly the primacy of HK-II displacement and the biphasic Warburg response, while investigating the singular thread regarding a quantitative cofactor occupancy model.]\n\n\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\n\nSECTION 1: DECOMPOSITION\n1. What is the sequence of molecular events linking VDAC1 cofactor displacement (by CBD/erastin) to cytochrome c release? Is it direct pore formation or a permissive signal for downstream effectors (Bax, lipids)?\n2. How does the pre-existing cofactor landscape (HK-II, Bcl-xL, tubulin, lipids) create a tunable threshold for apoptosis, and can this explain the biphasic CBD response in Warburg vs. normal cells?\n3. Can the apoptotic threshold [CBD] be predicted by a quantitative model of competitive cofactor occupancy? Does synergistic cofactor manipulation (2-DG+ABT-737) validate this model?\n\nKey variables: [CBD], HK-II-VDAC1 occupancy (function of [G6P]), Bcl-xL-VDAC1 occupancy, membrane lipid composition (CL:Chol ratio). Relationships: Cofactors compete for VDAC1 binding sites; displacement alters VDAC1 conformation/oligomerization propensity, gating access to CL and Bax recruitment.\n\n\u2500\u2500\u2500 SECTION 2: CLAIMS \u2500\u2500\u2500\n\nCLAIM 1: HK-II displacement from VDAC1 is a necessary permissive step that unmasks cardiolipin microdomains, enabling Bax recruitment and lipid peroxidation\u2014the primary driver of cytochrome c release. Direct VDAC1 conductance change is a secondary consequence of this membrane remodeling.\nTYPE: 1\nCONFIDENCE: 0.75\nMECHANISM: Displaced HK-II exposes CL, facilitating Bax insertion and ROS-induced CL peroxidation, which destabilizes the OMM and releases cyt c, while VDAC1 may subsequently adopt a sustained open state.\nFALSIFIABLE BY: Demonstrating cytochrome c release and apoptosis in cells where HK-II is displaced but CL peroxidation or Bax recruitment is pharmacologically/genetically blocked.\n\nCLAIM 2: The Warburg phenotype creates a biphasic CBD response because HK-II's ultra-high VDAC1 affinity (sub-nM) acts as a buffering capacitor; the apoptotic threshold [CBD] is defined by the product of (1 - fractional HK-II occupancy) and (1 - fractional Bcl-xL occupancy), explaining protection at low dose (<5 \u00b5M) and sensitization at high dose (>11 \u00b5M).\nTYPE: 2\nCONFIDENCE: 0.68\nMECHANISM: Low [CBD] primarily engages lower-Kd targets (TRPV1, PPAR\u03b3) promoting survival, while high [CBD] saturates the HK-II buffer via mass action, triggering cofactor displacement and the oligomerization cascade.\nFALSIFIABLE BY: Measuring precise HK-II-VDAC1 occupancy vs. [CBD] and showing apoptosis initiates only after occupancy falls below a fixed threshold, independent of other CBD targets.\n\nCLAIM 3: The synergistic apoptosis induced by 2-DG + ABT-737 arises because they multiplicatively reduce the cofactor \"clamp\" on VDAC1 oligomerization, shifting the dose-response of a VDAC1-binding molecule (e.g., CBD) leftward by a predictable factor based on occupancy reduction.\nTYPE: 2\nCONFIDENCE: 0.60\nMECHANISM: 2-DG (via G6P depletion) reduces HK-II-VDAC1 affinity, ABT-737 displaces Bcl-xL; their combined effect on the occupancy product lowers the energy barrier for VDAC1 conformational change to a pro-apoptotic state.\nFALSIFIABLE BY: Testing the combination with a range of VDAC1 binders and showing synergy collapses if either cofactor's binding is rendered irreversible.\n\n\u2500\u2500\u2500 SECTION 3: UNKNOWNS \u2500\u2500\u2500\n1. The precise quantitative occupancy of VDAC1 by HK-II and Bcl-xL as a function of [G6P] and [CBD] in living cells. Without these binding isotherms, the predictive model remains speculative.\n2. The exact lipid composition (CL vs. cholesterol) of the OMM microdomain surrounding VDAC1 in cancer vs. normal cells, and how this modulates the oligomerization efficiency of cofactor-free VDAC1.\n3. Whether CBD binding to VDAC1 directly induces a conductance change at apoptotic concentrations, or if the observed electrophysiology is purely an artifact of subsequent membrane disruption by Bax/CL.\n\n\u2500\u2500\u2500 SECTION 4: NEXT STEP \u2500\u2500\u2500\nQuantify HK-II-VDAC1 and Bcl-xL-VDAC1 co-occupancy via in-cell FRET/BRET alongside dose-response apoptosis curves for CBD \u00b1 2-DG/ABT-737 in isogenic Warburg-high vs. Warburg-low cells.",
      "claims": [
        {
          "statement": "1: HK-II displacement from VDAC1 is a necessary permissive step that unmasks cardiolipin microdomains, enabling Bax recruitment and lipid peroxidation\u2014the primary driver of cytochrome c release. Direct VDAC1 conductance change is a secondary consequence of this membrane remodeling.",
          "type": 1,
          "confidence": 0.75,
          "mechanism": "Displaced HK-II exposes CL, facilitating Bax insertion and ROS-induced CL peroxidation, which destabilizes the OMM and releases cyt c, while VDAC1 may subsequently adopt a sustained open state.",
          "falsifiable_by": "Demonstrating cytochrome c release and apoptosis in cells where HK-II is displaced but CL peroxidation or Bax recruitment is pharmacologically/genetically blocked."
        },
        {
          "statement": "2: The Warburg phenotype creates a biphasic CBD response because HK-II's ultra-high VDAC1 affinity (sub-nM) acts as a buffering capacitor; the apoptotic threshold [CBD] is defined by the product of (1 - fractional HK-II occupancy) and (1 - fractional Bcl-xL occupancy), explaining protection at low dose (<5 \u00b5M) and sensitization at high dose (>11 \u00b5M).",
          "type": 2,
          "confidence": 0.68,
          "mechanism": "Low [CBD] primarily engages lower-Kd targets (TRPV1, PPAR\u03b3) promoting survival, while high [CBD] saturates the HK-II buffer via mass action, triggering cofactor displacement and the oligomerization cascade.",
          "falsifiable_by": "Measuring precise HK-II-VDAC1 occupancy vs. [CBD] and showing apoptosis initiates only after occupancy falls below a fixed threshold, independent of other CBD targets."
        },
        {
          "statement": "3: The synergistic apoptosis induced by 2-DG + ABT-737 arises because they multiplicatively reduce the cofactor \"clamp\" on VDAC1 oligomerization, shifting the dose-response of a VDAC1-binding molecule (e.g., CBD) leftward by a predictable factor based on occupancy reduction.",
          "type": 2,
          "confidence": 0.6,
          "mechanism": "2-DG (via G6P depletion) reduces HK-II-VDAC1 affinity, ABT-737 displaces Bcl-xL; their combined effect on the occupancy product lowers the energy barrier for VDAC1 conformational change to a pro-apoptotic state.",
          "falsifiable_by": "Testing the combination with a range of VDAC1 binders and showing synergy collapses if either cofactor's binding is rendered irreversible. \u2500\u2500\u2500"
        }
      ]
    }
  ],
  "snapshot": {
    "round_num": 0,
    "jaccard": 0.05742424242424242,
    "cosine": 0.7937113642692566,
    "jsd": 0.15728103989791886,
    "kappa": 0.9139384129186418,
    "type_distribution": {
      "0": 0.0,
      "1": 0.42105263157894735,
      "2": 0.47368421052631576,
      "3": 0.10526315789473684
    },
    "type_01_ratio": 0.42105263157894735,
    "n_claims_per_model": [
      4,
      4,
      5,
      3,
      3
    ]
  },
  "total_calls": 5
}